miRNA-204-5p acts as tumor suppressor to influence the invasion and migration of astrocytoma by targeting ezrin and is downregulated by DNA methylation

References

• Shuangshoti S, Thorner PS, Ruangvejvorachai P, et al. J1-31 protein expression in astrocytes and astrocytomas. Neuropathology. 2009 Oct;29(5):521–527.
   PubMed Web of Science ®Google Scholar
• Gabayan AJ, Green SB, Sanan A, et al. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery. 2006Apr; 582: 701–709. discussion 701-709
   PubMedGoogle Scholar
• Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):709–722.
   PubMed Web of Science ®Google Scholar
• Seifert M, Garbe M, Friedrich B, et al. Comparative transcriptomics reveals similarities and differences between astrocytoma grades. BMC Cancer. 2015 Dec;16(15):952.
   Google Scholar
• Lu M, Wang Y, Zhou S, et al. MicroRNA-370 suppresses the progression and proliferation of human astrocytoma and glioblastoma by negatively regulating β-catenin and causing activation of FOXO3a. Exp Ther Med. 2018 Jan;15(1):1093–1098.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro-Oncol. 2013 Nov;15(Suppl 2):ii1–56.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Maruyama R, Yamamoto E, et al. Epigenetic alteration and microRNA dysregulation in cancer. Front Genet. 2013 Dec;3(4):258.
   Google Scholar
• Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012 Jul 6;150(1):12–27.
   PubMed Web of Science ®Google Scholar
• Yang Y, Huang J-Q, Zhang X, et al. MiR-129-2 functions as a tumor suppressor in glioma cells by targeting HMGB1 and is down-regulated by DNA methylation. Mol Cell Biochem. 2015 Jun;404(1–2):229–239.
   PubMed Web of Science ®Google Scholar
• Tajima M, Ohsaki T, Okazawa M, et al. Availability of oral swab sample for the detection of bovine viral diarrhea virus (BVDV) gene from the cattle persistently infected with BVDV. Jpn J Vet Res. 2008 May;56(1):3–8.
   PubMed Web of Science ®Google Scholar
• Kadir Y, Christine F, Barbara B-W, et al. Genetic heterogeneity of bovine viral diarrhoea virus (BVDV) isolates from Turkey: identification of a new subgroup in BVDV-1. Vet Microbiol. 2008 Aug 1;130(3–4):258–267.
   PubMed Web of Science ®Google Scholar
• Friedman RC, Farh KK-H, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009 Jan;19(1):92–105.
   PubMed Web of Science ®Google Scholar
• Ying Z, Li Y, Wu J, et al. Loss of miR-204 expression enhances glioma migration and stem cell-like phenotype. Cancer Res. 2013 Jan 15;73(2):990–999.
   PubMed Web of Science ®Google Scholar
• Xia Z, Liu F, Zhang J, et al. Decreased expression of MiRNA-204-5p contributes to glioma progression and promotes glioma cell growth, migration and invasion. PLOS ONE. 2015 Jul 2;10(7):e0132399.
   PubMed Web of Science ®Google Scholar
• Mao J, Zhang M, Zhong M, et al. MicroRNA-204, a direct negative regulator of ezrin gene expression, inhibits glioma cell migration and invasion. Mol Cell Biochem. 2014 Nov;396(1–2):117–128.
   PubMed Web of Science ®Google Scholar
• Karpenko MJ, Liu Z, Aimiuwu J, et al. Phase I study of 5-aza-2ʹ-deoxycytidine in combination with valproic acid in patients with NSCLC. J Clin Oncol. 2008 May 20;26(15_suppl):3502.
   Web of Science ®Google Scholar
• Hall DP, Cost NG, Hegde S, et al. TRPM3 and miR-204 establish a regulatory circuit that controls oncogenic autophagy in clear cell renal cell carcinoma. Cancer Cell. 2014 Nov 10;26(5):738–753.
   PubMed Web of Science ®Google Scholar
• Türker Şener L, Albeniz G, Dinç B, et al. iCELLigence real-time cell analysis system for examining the cytotoxicity of drugs to cancer cell lines. Exp Ther Med. 2017 Sep;14(3):1866–1870.
   PubMed Web of Science ®Google Scholar
• Courboulin A, Paulin R, Giguère NJ, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011 Mar 14;208(3):535–548.
   PubMed Web of Science ®Google Scholar
• Wen P, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008 Aug;1(359):492–507.
   Google Scholar
• Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007 Nov 1;21(21):2683–2710.
   PubMed Web of Science ®Google Scholar
• Lashford LS, Thiesse P, Jouvet A, et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children’s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol Off J Am Soc Clin Oncol. 2002 Dec 15;20(24):4684–4691.
   PubMed Web of Science ®Google Scholar
• Lefranc F, Le Rhun E, Kiss R, et al. Glioblastoma quo vadis: will migration and invasiveness reemerge as therapeutic targets? Cancer Treat Rev. 2018 Jul;68:145–154.
   PubMed Web of Science ®Google Scholar
• Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015 Jun;15(6):321–333.
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs — microRNAs with a role in cancer. Nat Rev Cancer. 2006 Apr;6(4):259–269.
   PubMed Web of Science ®Google Scholar
• Bader A. miR-34 – a microRNA replacement therapy is headed to the clinic. Front Genet. 2012;3:120.
   PubMedGoogle Scholar
• van Rooij E, Purcell AL, Levin AA. Developing MicroRNA therapeutics. Circ Res. 2012 Feb 3;110(3):496–507.
   PubMed Web of Science ®Google Scholar
• Zeng J, Wei M, Shi R, et al. MiR-204-5p/Six1 feedback loop promotes epithelial-mesenchymal transition in breast cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2016 Feb;37(2):2729–2735.
   PubMedGoogle Scholar
• Li W, Jin X, Zhang Q, et al. Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. Int J Clin Exp Pathol. 2014;7(6):3287–3292.
   PubMed Web of Science ®Google Scholar
• Bao W, Wang -H-H, Tian F-J, et al. A TrkB–STAT3–miR-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells. Mol Cancer. 2013 Dec 9;12(1):155.
   PubMedGoogle Scholar
• Chen Z, Sangwan V, Banerjee S, et al. miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death. Mol Cancer. 2013 Sep 11;12(1):105.
   PubMedGoogle Scholar
• Sacconi A, Biagioni F, Canu V, et al. miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis. 2012 Nov 15;3:e423.
   PubMed Web of Science ®Google Scholar
• Li L-Q, Pan D, Chen Q, et al. Sensitization of gastric cancer cells to 5-FU by MicroRNA-204 through targeting the TGFBR2-mediated epithelial to mesenchymal transition. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2018;47(4):1533–1545.
   PubMedGoogle Scholar
• Mikhaylova O, Stratton Y, Hall D, et al. VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma. Cancer Cell. 2012 Apr 17;21(4):532–546.
   PubMed Web of Science ®Google Scholar
• Lee Y, Yang X, Huang Y, et al. Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLoS Comput Biol. 2010 Apr 1;6(4):e1000730.
   PubMed Web of Science ®Google Scholar
• Arif KMT, Elliott EK, Haupt LM, et al. Regulatory mechanisms of epigenetic miRNA relationships in human cancer and potential as therapeutic targets. Cancers (Basel). 2020 Oct 11;12(10):2922.
   PubMed Web of Science ®Google Scholar
• Yang N, Coukos G, Zhang L. MicroRNA epigenetic alterations in human cancer: one step forward in diagnosis and treatment. Int J Cancer. 2008;122(5):963–968.
   PubMed Web of Science ®Google Scholar
• Zang L, Kondengaden SM, Che F, et al. Potential epigenetic-based therapeutic targets for glioma. Front Mol Neurosci. 2018 Nov;15(11):408.
   Google Scholar
• Tuna M, Machado AS, Calin GA. Genetic and epigenetic alterations of microRNAs and implications for human cancers and other diseases. Genes Chromosomes Cancer. 2016;55(3):193–214.
   PubMed Web of Science ®Google Scholar
• Sławek S, Szmyt K, Fularz M, et al. Pluripotency transcription factors in lung cancer—a review. Tumor Biol. 2016 Apr 1;37(4):4241–4249.
   PubMedGoogle Scholar
• Xia F, Wang W, Jiang B, et al. DNA methylation-mediated silencing of miR-204 is a potential prognostic marker for papillary thyroid carcinoma. Cancer Manag Res. 2019 Feb 8;11:1249–1262.
   PubMed Web of Science ®Google Scholar
• Mao J, Yuan X, Xu S, et al. Expression and functional significance of ezrin in human brain astrocytoma. Cell Biochem Biophys. 2013 Dec 1;67(3):1507–1511.
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Sharma AR, Sharma G, et al. The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer. Oncotarget. 2018 Jan 23;9(11):10164–10174.
   PubMedGoogle Scholar
• Broderick JA, Zamore PD. MicroRNA therapeutics. Gene Ther. 2011 Dec;18(12):1104–1110.
   PubMed Web of Science ®Google Scholar
• Garzon R, Marcucci G, Croce CM. Targeting MicroRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010 Oct;9(10):775–789.
   PubMed Web of Science ®Google Scholar
• Mollaei H, Safaralizadeh R, Rostami Z. MicroRNA replacement therapy in cancer. J Cell Physiol. 2019;234(8):12369–12384.
   PubMed Web of Science ®Google Scholar
• Zhuang Z, Yu P, Xie N, et al. MicroRNA-204-5p is a tumor suppressor and potential therapeutic target in head and neck squamous cell carcinoma. Theranostics. 2020 Jan 1;10(3):1433–1453.
   PubMed Web of Science ®Google Scholar
• Zheng B, Chen L, Pan -C-C, et al. Targeted delivery of miRNA-204-5p by PEGylated polymer nanoparticles for colon cancer therapy. Nanomed. 2018 Apr 1;13(7):769–785.
   PubMed Web of Science ®Google Scholar
• Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol. 2016 Sep;8(9):a019505.
   PubMed Web of Science ®Google Scholar
• Cheng Y, He C, Wang M, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019 Dec 17;4(1):1–39.
   PubMedGoogle Scholar
• Jin N, George TL, Otterson GA, et al. Advances in epigenetic therapeutics with focus on solid tumors. Clin Epigenetics. 2021 Apr 20;13(1):83.
   PubMed Web of Science ®Google Scholar
• Krauze AV, Myrehaug SD, Chang MG, et al. A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):986–992.
   PubMed Web of Science ®Google Scholar